Sfoglia per AUTORE
DI BELLA S
Collezione ASL Asti

  

Items : 8

A subanalysis of Clostridium perfringens bloodstream infections from a 5-year retrospective nationwide survey (ITANAEROBY). in Anaerobe / Anaerobe. 2024 Dec;90:102901. doi: 10.1016/j.anaerobe.2024.102901. Epub 2024 Aug 28.

2024
ASL Asti
AOU Città della Salute di Torino

Di Bella S; Luzzati R; Antonello RM; Zerbato V; Sanson G; Principe L; Geremia N;

Anaerobic bloodstream infections in Italy (ITANAEROBY): A 5-year retrospective nationwide survey. in Anaerobe / Anaerobe. 2022 Jun;75:102583. doi: 10.1016/j.anaerobe.2022.102583. Epub 2022 May 11.

2022
ASL Asti
AOU Città della Salute di Torino

Parisio EM; Pagani E; Mosca A; Morroni G; Mauri C; Luzzaro F; Bianco G; Concialdi E; Lupia T; Intra J; Knezevich A; Greco F; Gargiulo R; Dodaro S; De Rosa FG; Chilleri C; Cassetti T; Carretto E; Camarlinghi G; Carcione D; Busetti M; Bielli A; Bernardo M; Bartolini L; Aschbacher R; Ambretti S; Sepulcri C; Giacobbe DR; Maraolo AE; et alii...

Temocillin: Applications in Antimicrobial Stewardship as a Potential Carbapenem-Sparing Antibiotic. in Antibiotics (Basel, Switzerland) / Antibiotics (Basel). 2022 Apr 7;11(4):493. doi: 10.3390/antibiotics11040493.

2022
ASL Asti

Lupia T; De Benedetto I; Stroffolini G; Di Bella S; Mornese Pinna S; Zerbato V; Rizzello B; Bosio R; Shbaklo N; Corcione S; De Rosa FG;

Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: ?-Lactam/?-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians. in Pharmaceuticals (Basel, Switzerland) / Pharmaceuticals (Basel). 2022 Apr 12;15(4):463. doi: 10.3390/ph15040463.

2022
ASL Asti

Principe L; Lupia T; Andriani L; Campanile F; Carcione D; Corcione S; De Rosa FG; Luzzati R; Stroffolini G; Steyde M; Decorti G; Di Bella S;

Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses in The Lancet

2022
ASL Asti

Pan H; Peto R; Hernández-García C; Røttingen J-A; Swaminathan S; Ryan M; Maggioni A; Babiker A; Cook D; Dondorp A; Kang G; Trelle S; McGinty S; Branca M; Appadoo S; Sauermann M; Sterne JAC; Rogers CA; Cappel-Porter H; Hutton D; Bellani S; Allum E; Kirwan J; Benassi V; Henao-Restrepo A-M; Lydon P; Miranda-Montoya MC; Preziosi M-P; Salami K; et alii...

Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: ?-Lactam/?-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians in Pharmaceuticals

2022
ASL Asti

Principe L; Lupia T; Andriani L; Campanile F; Carcione D; Corcione S; De Rosa FG; Luzzati R; Stroffolini G; Steyde M; Decorti G; Di Bella S;

Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: ?-Lactam/?-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians in Pharmaceuticals

2022
ASL Asti

Principe L; Lupia T; Andriani L; Campanile F; Carcione D; Corcione S; De Rosa FG; Luzzati R; Stroffolini G; Steyde M; Decorti G; Di Bella S;

Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: ?-Lactam/?-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians in Pharmaceuticals

2022
ASL Asti

Principe L; Lupia T; Andriani L; Campanile F; Carcione D; Corcione S; De Rosa FG; Luzzati R; Stroffolini G; Steyde M; Decorti G; Di Bella S;